The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass
Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and
Meta-analysis of Randomized Controlled Trials

Leila      Khalili; Srinivas      Nammi

doi:10.2174/1381612828666220328111141

Abstract

Background and Aims: Curcumin is one of the most commonly used indigenous molecules endowed with various shielding functionalities that protect the liver. In the present research, we aimed to investigate the effects of curcumin on metabolic factors and body mass index (BMI) in patients with non-alcoholic fatty liver disease (NAFLD) using a meta-analysis of randomized, controlled trials.

Methods: Online databases PubMed, Embase, Web of Science, and Science Direct were searched until April 2021 to identify eligible articles. Fourteen trials were included.

Results: The results showed that curcumin consumption can significantly reduce AST (-0.35, (-0.57 to -0.14)), total cholesterol (-0.81, (-1.34 to -0.27)), TG (-0.49, (-0.71 to -0.27)), and FBS (-0.28, (-0.46 to -0.09)) in patients with NAFLD. However, the improvements in ALT (-0.29, (-0.58 to 0.00)), LDL (-0.48, (-0.97 to 0.01)), HDL (0.03, (-0.38 to 0.44)), and BMI (-0.13, (-0.29 to 0.02)) were not statistically significant. Furthermore, the findings revealed that the optimal dose and duration of curcumin consumption for patients with NAFLD is <500 mg/d for less than 10 weeks.

Conclusion: The present study suggests that consuming curcumin can improve liver enzymes, lipid profile, FBS, and BMI in patients with NAFLD. Moreover, curcumin supplementation may provide beneficial effects on metabolic biomarkers and body weight if used at the appropriate dose and duration. Further RCTs are required to confirm our findings.

Keywords: Meta-analysis, curcumin, NAFLD, metabolic biomarkers, BMI, liver enzymes.

« Previous Next »

[1] 
Chashmniam S, Mirhafez SR, Dehabeh M, et al. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr  2019; 73(9): 1224-35.
[http://dx.doi.org/10.1038/s41430-018-0386-5] [PMID:  30647436] 
[2] 
Mansour-Ghanaei F, Pourmasoumi M, Hadi A, Joukar F. Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials. Integr Med Res  2019; 8(1): 57-61.
[http://dx.doi.org/10.1016/j.imr.2018.07.004] [PMID:  30949432] 
[3] 
White CM, Lee JY. The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: A systematic review of clinical trials. Pharm Pract (Granada)  2019; 17(1): 1350.
[http://dx.doi.org/10.18549/PharmPract.2019.1.1350] [PMID:  31015871] 
[4] 
Farzaei MH, Zobeiri M, Parvizi F, et al. Curcumin in liver diseases: A systematic review of the cellular mechanisms of oxidative stress and clinical perspective. Nutrients  2018; 10(7): 855.
[http://dx.doi.org/10.3390/nu10070855] [PMID:  29966389] 
[5] 
Tabrizi R, Vakili S, Lankarani KB, et al. The effects of curcumin on glycemic control and lipid profiles among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des  2018; 24(27): 3184-99.
[http://dx.doi.org/10.2174/1381612824666180828162053] [PMID:  30156145] 
[6] 
Hassanalilou T, Ghavamzadeh S, Khalili L. Curcumin and gastric cancer: A review on mechanisms of action. J Gastrointest Cancer  2019; 50(2): 185-92.
[http://dx.doi.org/10.1007/s12029-018-00186-6] [PMID:  30725357] 
[7] 
Kam A, Li KM, Razmovski-Naumovski V, et al. Curcumin reduces tumour necrosis factor-enhanced annexin V-positive microparticle release in human vascular endothelial cells. J Pharm Pharm Sci  2015; 18(4): 424-33.
[http://dx.doi.org/10.18433/J3ZC8G] [PMID:  26626244] 
[8] 
Mukhopadhyay S, Mondal SA, Kumar M, Dutta D. Proinflammatory and antiinflammatory attributes of fetuin-a: A novel hepatokine modulating cardiovascular and glycemic outcomes in metabolic syndrome. Endocr Pract  2014; 20(12): 1345-51.
[http://dx.doi.org/10.4158/EP14421.RA] [PMID:  25370330] 
[9] 
Tranchida F, Rakotoniaina Z, Shintu L, et al. Hepatic metabolic effects of Curcuma longa extract supplement in high-fructose and saturated fat fed rats. Sci Rep  2017; 7(1): 5880.
[http://dx.doi.org/10.1038/s41598-017-06220-0] [PMID:  28724959] 
[10] 
Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: A randomized controlled trial. J Cardiovasc Pharmacol  2016; 68(3): 223-9.
[http://dx.doi.org/10.1097/FJC.0000000000000406] [PMID:  27124606] 
[11] 
Shin SK, Ha TY, McGregor RA, Choi MS. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res  2011; 55(12): 1829-40.
[http://dx.doi.org/10.1002/mnfr.201100440] [PMID:  22058071] 
[12] 
Rahimi HR, Mohammadpour AH, Dastani M, et al. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: A randomized clinical trial. Avicenna J Phytomed  2016; 6(5): 567-77.
[PMID:  27761427] 
[13] 
Mohammadi A, Sahebkar A, Iranshahi M, et al. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: A randomized crossover trial. Phytother Res  2013; 27(3): 374-9.
[http://dx.doi.org/10.1002/ptr.4715] [PMID:  22610853] 
[14] 
Mirhafez SR, Farimani AR, Dehhabe M, et al. Effect of phytosomal curcumin on circulating levels of adiponectin and leptin in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. J Gastrointestin Liver Dis  2019; 28(2): 183-9.
[http://dx.doi.org/10.15403/jgld-179] [PMID:  31204416] 
[15] 
Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, et al. Nano-curcumin im0proves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with Non-Alcoholic Fatty Liver Disease (NAFLD): A double-blind randomized placebo-controlled clinical trial. Nutr Metab (Lond)  2019; 16(1): 8.
[http://dx.doi.org/10.1186/s12986-019-0331-1] [PMID:  30705687] 
[16] 
Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: A randomized controlled trial. Drug Res (Stuttg)  2017; 67(4): 244-51.
[http://dx.doi.org/10.1055/s-0043-100019] [PMID:  28158893] 
[17] 
Kelardeh BM, Rahmati-Ahmadabad S, Farzanegi P, Helalizadeh M, Azarbayjani MA. Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease. J Bodyw Mov Ther  2020; 24(3): 154-60.
[http://dx.doi.org/10.1016/j.jbmt.2020.02.021] [PMID:  32825982] 
[18] 
Saadati S, Hekmatdoost A, Hatami B, et al. Comparing different non-invasive methods in assessment of the effects of curcumin on hepatic fibrosis in patients with non-alcoholic fatty liver disease. Gastroenterol Hepatol Bed Bench  2018; 11(Suppl. 1): S8-S13.
[PMID:  30774801] 
[19] 
Saadati S, Hatami B, Yari Z, et al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr  2019; 73(3): 441-9.
[http://dx.doi.org/10.1038/s41430-018-0382-9] [PMID:  30610213] 
[20] 
Saadati S, Sadeghi A, Mansour A, et al. Curcumin and inflammation in non-alcoholic fatty liver disease: A randomized, placebo controlled clinical trial. BMC Gastroenterol  2019; 19(1): 133.
[http://dx.doi.org/10.1186/s12876-019-1055-4] [PMID:  31345163] 
[21] 
Husain D, Jarahzadeh M, Alavinejad P, Rezazadeh A, Haghighizadeh M. Turmeric supplementation in nonalcoholic fatty liver disease. Plant Arch  2020; 20(2): 3640-7.
[22] 
Cicero AFG, Sahebkar A, Fogacci F, Bove M, Giovannini M, Borghi C. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: A double-blind, placebo-controlled clinical trial. Eur J Nutr  2020; 59(2): 477-83.
[http://dx.doi.org/10.1007/s00394-019-01916-7] [PMID:  30796508] 
[23] 
Nouri-Vaskeh M, Malek Mahdavi A, Afshan H, Alizadeh L, Zarei M. Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial. Phytother Res  2020; 34(6): 1446-54.
[http://dx.doi.org/10.1002/ptr.6620] [PMID:  32017253] 
[24] 
Hariri M, Gholami A, Mirhafez SR, Bidkhori M, Sahebkar A. A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial. Complement Ther Med  2020; 51: 102447.
[http://dx.doi.org/10.1016/j.ctim.2020.102447] [PMID:  32507446] 
[25] 
Rahmani S, Asgary S, Askari G, et al. Treatment of non‐alcoholic fatty liver disease with curcumin: A randomized placebo‐controlled trial. Phytother Res  2016; 30(9): 1540-8.
[http://dx.doi.org/10.1002/ptr.5659] [PMID:  27270872] 
[26] 
Saberi-Karimian M, Keshvari M, Ghayour-Mobarhan M, et al. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Complement Ther Med  2020; 49: 102322.
[http://dx.doi.org/10.1016/j.ctim.2020.102322] [PMID:  32147075] 
[27] 
Khalili L, Alipour B, Asghari Jafarabadi M, Hassanalilou T, Mesgari Abbasi M, Faraji I. Probiotic assisted weight management as a main factor for glycemic control in patients with type 2 diabetes: A randomized controlled trial. Diabetol Metab Syndr  2019; 11(1): 1-9.
[http://dx.doi.org/10.1186/s13098-019-0400-7] [PMID:  30675190] 
[28] 
Hassanalilou T, Payahoo L, Shahabi P, et al. The protective effects of Morus nigra L. leaves on the kidney function tests and histological structures in streptozotocin-induced diabetic rats. Biomedical Research-India  2017; 28(14): 6113-8.
[29] 
Payahoo L, Khajebishak Y, Alivand MR, et al. Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial. Appetite  2019; 141: 104301.
[http://dx.doi.org/10.1016/j.appet.2019.05.032] [PMID:  31132422] 
[30] 
Khalili L, Valdes-Ramos R, Harbige LS. Effect of n-3 (Omega-3) polyunsaturated fatty acid supplementation on metabolic and inflammatory biomarkers and body weight in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of RCTs. Metabolites  2021; 11(11): 742.
[http://dx.doi.org/10.3390/metabo11110742] [PMID:  34822400] 
[31] 
Wei Z, Liu N, Tantai X, et al. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Hepatol Int  2019; 13(3): 302-13.
[http://dx.doi.org/10.1007/s12072-018-9910-x] [PMID:  30446932] 
[32] 
Kunnumakkara AB, Bordoloi D, Padmavathi G, et al. Curcumin, the golden nutraceutical: Multitargeting for multiple chronic diseases. Br J Pharmacol  2017; 174(11): 1325-48.
[http://dx.doi.org/10.1111/bph.13621] [PMID:  27638428] 
[33] 
Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver Int  2009; 29(10): 1457-66.
[http://dx.doi.org/10.1111/j.1478-3231.2009.02086.x] [PMID:  19811613] 
[34] 
Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-κ B-dependent genes. Am J Physiol Gastrointest Liver Physiol  2003; 284(2): G321-7.
[http://dx.doi.org/10.1152/ajpgi.00230.2002] [PMID:  12388178] 
[35] 
Vizzutti F, Provenzano A, Galastri S, et al. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Invest  2010; 90(1): 104-15.
[http://dx.doi.org/10.1038/labinvest.2009.112] [PMID:  19901911] 
[36] 
Ramirez-Tortosa MC, Ramirez-Tortosa CL, Mesa MD, Granados S, Gil A, Quiles JL. Curcumin ameliorates rabbits’s steatohepatitis via respiratory chain, oxidative stress, and TNF-α. Free Radic Biol Med  2009; 47(7): 924-31.
[http://dx.doi.org/10.1016/j.freeradbiomed.2009.06.015] [PMID:  19539747] 
[37] 
Adibian M, Hodaei H, Nikpayam O, Sohrab G, Hekmatdoost A, Hedayati M. The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Phytother Res  2019; 33(5): 1374-83.
[http://dx.doi.org/10.1002/ptr.6328] [PMID:  30864188] 
[38] 
Egashira K, Sasaki H, Higuchi S, Ieiri I. Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats. Drug Metab Pharmacokinet  2012; 27(2): 242-7.
[http://dx.doi.org/10.2133/dmpk.DMPK-11-RG-105] [PMID:  22123127] 
[39] 
Salomone F, Godos J, Zelber-Sagi S. Natural antioxidants for non-alcoholic fatty liver disease: Molecular targets and clinical perspectives. Liver Int  2016; 36(1): 5-20.
[http://dx.doi.org/10.1111/liv.12975] [PMID:  26436447] 
[40] 
Afrin R, Arumugam S, Rahman A, et al. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation. Int Immunopharmacol  2017; 44: 174-82.
[http://dx.doi.org/10.1016/j.intimp.2017.01.016] [PMID:  28110063] 
[41] 
Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits gene expression of Receptor for Advanced Glycation End-products (RAGE) in hepatic stellate cells in vitro by elevating PPARγ activity and attenuating oxidative stress. Br J Pharmacol  2012; 166(8): 2212-27.
[http://dx.doi.org/10.1111/j.1476-5381.2012.01910.x] [PMID:  22352842] 
[42] 
Calabrese V, Bates TE, Mancuso C, et al. Curcumin and the cellular stress response in free radical-related diseases. Mol Nutr Food Res  2008; 52(9): 1062-73.
[http://dx.doi.org/10.1002/mnfr.200700316] [PMID:  18792015] 
[43] 
Ghelani H, Razmovski-Naumovski V, Chang D, Nammi S. Chronic treatment of curcumin improves hepatic lipid metabolism and alleviates the renal damage in adenine-induced chronic kidney disease in Sprague-Dawley rats. BMC Nephrol  2019; 20(1): 431.
[http://dx.doi.org/10.1186/s12882-019-1621-6] [PMID:  31752737] 
[44] 
Arafa HM. Curcumin attenuates diet-induced hypercholesterolemia in rats. Med Sci Monit  2005; 11(7): BR228-34.
[PMID:  15990684] 
[45] 
Sukandar E, Permana H, Adnyana I, et al. Clinical study of turmeric (Curcuma longa L.) and garlic (Allium sativum L.) extracts as antihyperglycemic and antihyperlipidemic agent in type-2 diabetes-dyslipidemia patients. Int J Pharmacol  2010; 6(4): 456-63.
[http://dx.doi.org/10.3923/ijp.2010.456.463] 
[46] 
Mauren FM, Yanti BWL, Lay BW. Efficacy of oral curcuminoid fraction from curcuma xanthorrhiza and curcuminoid cider in high-cholesterol fed rats. Pharmacognosy Res  2016; 8(3): 153-9.
[http://dx.doi.org/10.4103/0974-8490.181468] [PMID:  27365981] 
[47] 
Shao W, Yu Z, Chiang Y, et al. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One  2012; 7(1): e28784.
[http://dx.doi.org/10.1371/journal.pone.0028784] [PMID:  22253696] 
[48] 
Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol  2009; 41(1): 40-59.
[http://dx.doi.org/10.1016/j.biocel.2008.06.010] [PMID:  18662800] 
[49] 
Poolsup N, Suksomboon N, Kurnianta PDM, Deawjaroen K. Effects of curcumin on glycemic control and lipid profile in prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis. PLoS One  2019; 14(4): e0215840.
[http://dx.doi.org/10.1371/journal.pone.0215840] [PMID:  31013312] 
[50] 
Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science  2011; 334(6052): 105-8.
[http://dx.doi.org/10.1126/science.1208344] [PMID:  21885731] 
[51] 
Deng YT, Chang TW, Lee MS, Lin JK. Suppression of free fatty acid-induced insulin resistance by phytopolyphenols in C2C12 mouse skeletal muscle cells. J Agric Food Chem  2012; 60(4): 1059-66.
[http://dx.doi.org/10.1021/jf204496f] [PMID:  22191431] 
[52] 
Pu Y, Zhang H, Wang P, et al. Dietary curcumin ameliorates aging-related cerebrovascular dysfunction through the AMPK/] uncoupling protein 2 pathway. Cell Physiol Biochem  2013; 32(5): 1167-77.
[http://dx.doi.org/10.1159/000354516] [PMID:  24335167] 
[53] 
Akbari M, Lankarani KB, Tabrizi R, et al. The effects of curcumin on weight loss among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol  2019; 10: 649.
[http://dx.doi.org/10.3389/fphar.2019.00649] [PMID:  31249528] 

Rights & Permissions Print Cite

Article Metrics

23

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1381612828666220328111141	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

Current Pharmaceutical Design

The Effects of Curcumin Supplementation on Metabolic Biomarkers and Body Mass Index in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Abstract Play Pause

Related Journals

Related Books

Abstract